Outsourced Pharma White Papers

  1. White Paper: Nasal Delivery Of Spray Dried Biologics: Opportunities And Challenges 10/16/2024

    Explore the potential of spray-dried nasal formulations for biologics to achieve excellent stability and targeted delivery, paving the way for innovative and effective therapeutic solutions.

  2. A Scalable Platform To Revolutionize Gene Therapy Manufacturing 11/22/2024

    Discover how our innovative rAAV production platform can revolutionize your gene therapy pipeline with unparalleled yield, quality, and scalability.

  3. Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge SCID Mouse Models 6/10/2025

    Advance your RSV therapeutic pipeline with trusted, IND-enabling preclinical services that deliver clinically relevant data through optimized study designs and validated rodent models.

  4. The Problem With Construction Quality 10/21/2024

    Data center construction quality management is inadequate, with issues traced to human error. A stronger focus on quality control and assurance is needed for success.

  5. Manufacturing Of Cytotoxic And Non-Cytotoxic Drugs In A Multiproduct Facility 10/16/2024

    The experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end-user.

  6. Predictive Modeling Of Viscosity Behavior Using Artificial Neural Networks 9/11/2023

    Discover a modeling approach employing artificial neural networks using experimental factors combined with simulation-derived parameters plus viscosity data from 27 highly concentrated mAbs.

  7. Setting The Standard For Plasmid DNA Production 10/16/2024

    Discover how Boehringer Ingelheim’s expertise in plasmid DNA manufacturing can propel your innovative therapies forward and transform patient care.

  8. Random & Semi-Targeted Integration In Cell Line Development 8/5/2025

    Compare random and semi-targeted integration strategies for stable cell line development, highlighting their impact on expression consistency, scalability, and regulatory considerations.

  9. Preclinical Evaluation Of New Antifibrotics In NASH-Induced Fibrosis Models 6/10/2025

    Accelerate the development of antifibrotic therapies through our clinically relevant models, deep scientific expertise, and proven preclinical capabilities in this area of unmet medical need.

  10. Overcoming Challenges To High-Concentration Formulation Development 3/25/2025

    Explore how the S-HiCon™ platform optimizes high-concentration therapeutic antibody formulations, overcoming stability and manufacturability challenges to deliver safe, effective therapies.